LIVITECH
LIVE

Serial Number

79329443

Owner

GENFIT

Attorney

Ronald M. Kachmarik

Filing Date

Oct 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

LIVITECH Trademark

Serial Number: 79329443 • Registration: 7033146

LIVITECH is a trademark filed by GENFIT on October 21, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

GENFIT (44 trademarks)

885 rue Eugene Avinee
Loos 59120 , FR

Entity Type: 03

Trademark Details

Filing Date

October 21, 2021

Registration Date

April 25, 2023

Published for Opposition

February 7, 2023

Goods & Services

Downloadable software for use in diagnosis of inflammatory diseases and liver diseases; downloadable software applications for use in diagnosing medical conditions; scientific apparatus and instruments especially for recording, processing, reproducing, transmitting data, namely, electronic data loggers and recorders; data processing equipment; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Pharmaceuticals for use in human or veterinary medicine, for scientific use for the treatment of inflammatory diseases and liver diseases; chemical preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; biological preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; microorganism cultures for use in human or veterinary medicine, or for pharmaceutical use; cell preparations for use in human or veterinary medicine, or for pharmaceutical use, in particular for gene therapy and cell therapy, namely, cell growth media; blood and blood derived samples, namely, plasma, serum, platelet free samples for medical use; diagnostic biomarker reagent products for use in human or veterinary medicine; diagnostic reagents for use in human or veterinary medicine; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Reagents for chemical analyses for scientific use; reagents for scientific use; reagents for scientific or medical research use; diagnostic reagents for scientific use; reagents for immunoserology and molecular diagnosis for research use; chemical reagents for genetic research; in-vivo diagnostic reagents for scientific use; diagnostic reagents for scientific use or for research use; diagnostic reagents for in-vitro use in biochemistry, molecular biology, clinical chemistry and microbiology for research use; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Medical analysis relating to the diagnosis and treatment of persons and medical diagnosis services in inflammatory diseases and liver diseases; medical analyses of blood samples, biological preparations and biological fluids relating to the diagnosis and treatment of persons; support services in the field of medicine, health care and pharmaceutical research, namely, medical analysis for the diagnosis and treatment of patients; medical information; provision of medical information; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Medical apparatus, instruments and equipment, namely, DNA, RNA and protein analysis apparatus, DNA, RNA and protein quantifiers, medical devices for measuring DNA, RNA, biochemical and physical parameters, namely, concentration of biomarkers relating to the evaluation of inflammatory and liver diseases and blood analyzers for evaluation of inflammatory and liver diseases; instruments and tools for medical diagnosis, namely, computer displays and computer monitors and controllers therefor used in direct association with medical diagnosis apparatus during the process of diagnosis of a condition in an individual; diagnostic apparatus for medical use, namely, medical diagnostic apparatus for testing the biomarker levels; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Pharmaceutical research, namely, research for the discovery of new medicines; scientific research, especially in the medical, biomedical, chemical, genetic, pharmaceutical field; basic and applied scientific research; technical scientific research; scientific research, namely, sorting and selection of molecules; scientific research services, namely, development and validation of biological tests, cellular tests and genetic tests; scientific research, namely, functional genomics for identifying, characterizing, validating and developing biologically active molecules; analysis of biological substances in biological fluids; computer programming in the field of scientific research and for the pharmaceutical industry; engineering services, namely, surveying; technical project study being scientific research; professional consultancy unrelated to business dealings in the field of scientific and medical research; research and development of new pharmaceutical products for others; scientific research in the field of pharmacy; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the public

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 28, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 3, 2023 FICS
FINAL DISPOSITION PROCESSED
Aug 3, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 25, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 25, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 25, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Feb 7, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 7, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 18, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 18, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 18, 2023 NONP
ASSIGNED TO EXAMINER
Jan 17, 2023 DOCK
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 31, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 31, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 31, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 31, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 31, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 27, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 27, 2022 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 24, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 24, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2022 TROA
REFUSAL PROCESSED BY IB
May 16, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 28, 2022 RFCS
REFUSAL PROCESSED BY MPU
Apr 28, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 18, 2022 RFCR
NON-FINAL ACTION WRITTEN
Mar 17, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 17, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 7, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 23, 2021 REPR